1. Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models.
- Author
-
Hong E, Park S, Ooshima A, Hong CP, Park J, Heo JS, Lee S, An H, Kang JM, Park SH, Park JO, and Kim SJ
- Subjects
- Aniline Compounds pharmacology, Aniline Compounds therapeutic use, Animals, Antineoplastic Combined Chemotherapy Protocols pharmacology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinogenesis drug effects, Carcinogenesis genetics, Carcinogenesis pathology, Cell Line, Tumor, Cell Movement drug effects, Disease Models, Animal, Drug Synergism, Epithelial-Mesenchymal Transition drug effects, Fluorouracil pharmacology, Gene Expression Regulation, Neoplastic drug effects, Irinotecan pharmacology, Leucovorin pharmacology, Liposomes, Mice, Inbred C57BL, Neoplasm Invasiveness, Pancreatic Neoplasms genetics, Survival Analysis, Transcriptome genetics, Triazoles pharmacology, Triazoles therapeutic use, Tumor Stem Cell Assay, Up-Regulation drug effects, Fluorouracil therapeutic use, Irinotecan therapeutic use, Leucovorin therapeutic use, Nanoparticles chemistry, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms pathology, Signal Transduction, Transforming Growth Factor beta metabolism
- Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies. TGF-β is strongly expressed in both the epithelial and stromal compartments of PDAC, and dysregulation of TGF-β signalling is a frequent molecular disturbance in PDAC progression and metastasis. In this study, we investigated whether blockade of TGF-β signalling synergizes with nal-IRI/5-FU/LV, a chemotherapy regimen for malignant pancreatic cancer, in an orthotopic pancreatic tumour mouse model. Compared to nal-IRI/5-FU/LV treatment, combining nal-IRI/5-FU/LV with vactosertib, a TGF-β signalling inhibitor, significantly improved long-term survival rates and effectively suppressed invasion to surrounding tissues. Through RNA-sequencing analysis, we identified that the combination treatment results in robust abrogation of tumour-promoting gene signatures and positive enrichment of tumour-suppressing and apoptotic gene signatures. Particularly, the expression of tumour-suppressing gene Ccdc80 was induced by vactosertib and further induced by vactosertib in combination with nal-IRI/5-FU/LV. Ectopic expression of CCDC80 suppressed migration and colony formation concomitant with decreased expression of epithelial-to-mesenchymal transition (EMT) markers in pancreatic cancer cells. Collectively, these results indicate that combination treatment of vactosertib with nal-IRI/5-FU/LV improves overall survival rates in a mouse model of pancreatic cancer by suppressing invasion through CCDC80. Therefore, combination therapy of nal-IRI/5-FU/LV with vactosertib could provide clinical benefits to pancreatic cancer patients.
- Published
- 2020
- Full Text
- View/download PDF